Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Protein PHGDH may predict immunotherapy success in colorectal cancer

NCT ID NCT07508046

Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from West China Hospital examined tumor tissue from 100 colorectal cancer patients who had already received immunotherapy. Researchers measured levels of a protein called PHGDH to see if it was linked to how well the patients responded to treatment and how long they lived. The goal was to find a simple marker that could help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If PHGDH proves to be a reliable marker, doctors could one day use it to decide which colorectal cancer patients are most likely to benefit from immunotherapy.
What could go wrong
This is an observational study that only looks back at existing data. It does not test a new treatment, so any link between PHGDH and outcomes is still unproven and needs much larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Nov 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a single-center, retrospective cohort study. The study population consists of patients with histologically confirmed colorectal adenocarcinoma who initiated immune checkpoint inhibitor therapy at \[Your Hospital Name\] between June 2018 and December 2025. Participants will be categorized into PHGDH-high and PHGDH-low groups based on the expression level of PHGDH protein in pre-treatment tumor tissue (assessed by immunohistochemistry). The primary objective is to compare the effectiveness of immunotherapy (e.g., progression-free survival) between the two groups.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with histologically confirmed colorectal adenocarcinoma. 2. Initiated treatment with immune checkpoint inhibitors (at least one cycle) between June 1, 2018 and December 31, 2025. 3. Availability of pre-treatment archival tumor tissue (FFPE block or slides) for PHGDH immunohistochemistry testing. 4. Have evaluable baseline radiographic images (CT or MRI) prior to immunotherapy. 5. Sufficient medical records for survival follow-up data extraction. Exclusion Criteria: 1. Unavailability of adequate tumor tissue for PHGDH expression analysis. 2. Permanently discontinued immunotherapy prior to the first scheduled radiological response assessment. 3. History of other active malignancies within the past 5 years (except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix). 4. Insufficient clinical documentation to determine the primary outcome (e.g., progression-free survival).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colo-rectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colo-rectal cancer

Contacts and locations

Locations

  • West China Hospital

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.